Intersect ENT (NASDAQ:XENT) stock price target increased to $17.00, issued a research note today by Deutsche Bank
- Updated: October 6, 2016
Just yesterday Intersect ENT (NASDAQ:XENT) traded -0.90% lower at $16.60. Intersect ENT’s 50-day moving average is $15.47 and its 200-day moving average is $15.48. The last stock price is up 6.25% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 13,796 shares of XENT traded hands, down from an average trading volume of 253,331
In a report released on 10/06/2016 Deutsche Bank increased the stock price target of Intersect ENT (NASDAQ:XENT) to $17.00 reporting a possible upside of 0.02%.
Previously on 3/29/2016, Northland Capital released a statement about Intersect ENT (NASDAQ:XENT) increased the target price from $0.00 to $26.00. At the time, this indicated a possible upside of 0.55%.
Recent Performance Chart
Intersect ENT has 52 week low of $11.88 and a 52 week high of $23.00 and has a market capitalization of $0.
In addition to Deutsche Bank reporting its stock price target, a total of 7 brokerages have issued a research note on the company. The average stock price target is $25.14 with 5 brokerages rating the stock a strong buy, 3 brokerages rating the stock a buy, 0 brokerages rating the stock a hold, 0 brokerages rating the stock a underperform, and finally 0 brokerages rating the stock a sell.
Brief Synopsis On Intersect ENT (NASDAQ:XENT)
Intersect ENT, Inc. is a commercial stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. It has developed a drug releasing bio-absorbable implant technology that enables targeted and sustained release of therapeutic agents. Its commercial products are the PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis. It is building a portfolio of products based on its drug releasing bio-absorbable implant technology that are designed to provide localized drug delivery to treat patients across the continuum of care in chronic sinusitis. Its steroid releasing implants are the drug releasing implants for chronic sinusitis sufferers. The PROPEL mini implant is a smaller version of PROPEL and is manufactured from the same bio-absorbable polymer fiber and with the same drug releasing coating and other design characteristics. It also developing NOVA, a steroid releasing implant.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.